PMPatricia W. Mueller

Patricia W. Mueller

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Patricia W. Mueller has a total of 21 co-authors. Here are the top co-authors by number of shared publications:

  • Polly J. Bingley

    Clinical Science at North Bristol (A.K.W., P.J.B.), University of Bristol, Southmead Hospital, Bristol BS10 5NB, United Kingdom

    2 shared publications
  • Samuel P. Caudill

    Centers for Disease Control and Prevention (CDC), National Center for Environmental Health, Division of Environmental Health Laboratory Sciences, Molecular Biology Branch, National Diabetes Laboratory, Atlanta, Georgia, USA

    2 shared publications
  • Alastair K. Williams

    Clinical Science at North Bristol (A.K.W., P.J.B.), University of Bristol, Southmead Hospital, Bristol BS10 5NB, United Kingdom

    1 shared publication
  • Anette G. Ziegler

    Diabetes Research Institute (K.A., A.G.Z.), Forschergruppe Diabetes e.V., 80804 Munich, Germany

    1 shared publication
  • Arvin Arepally

    Emory University School of Medicine , Atlanta, Georgia , USA

    1 shared publication
  • Beena Akolkar

    Division of Diabetes, Endocrinology, and Metabolic Diseases (B.A.), National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892

    1 shared publication

Latest Publications

  • Fragile X Syndrome

    by Justine I. Lyons, Gregory R. Kerr, Patricia W. Mueller


  • Open Access

    Harmonization of Glutamic Acid Decarboxylase and Islet Antigen-2 Autoantibody Assays for National Institute of Diabetes and Digestive and Kidney Diseases Consortia

    by Ezio Bonifacio, Liping Yu, Alastair K. Williams, George S. Eisenbarth, Polly J. Bingley, Santica M. Marcovina, Kerstin Adler, Anette G. Ziegler, Patricia W. Mueller, Desmond A. Schatz, et al.

    Background/Rationale: Autoantibodies to islet antigen-2 (IA-2A) and glutamic acid decarboxylase (GADA) are markers for diagnosis, screening, and measuring outcomes in National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) consortia studies. A harmonization program was established to increase comparability of results within and among these studies. Methods: Large volumes of six working calibrators were prepared from pooled sera with GADA 4.8–493 World Health Organization (WHO) units/ml and IA-2A 2–235 WHO units/ml. Harmonized assay protocols for IA-2A and GADA using 35S-methionine-labelled in vitro transcribed and translated antigens were developed based on methods in use in three NIDDK laboratories. Antibody thresholds were defined using sera from patients with recent onset type 1 diabetes and healthy controls. To evaluate the impact of the harmonized assay protocol on concordance of IA-2A and GADA results, two laboratories retested stored TEDDY study sera using the harmonized assays. Results: The harmonized assays gave comparable but not identical results in the three laboratories. For IA-2A, using a common threshold of 5 DK units/ml, 549 of 550 control and patient samples were concordantly scored as positive or negative, specificity was greater than 99% with sensitivity 64% in all laboratories. For GADA, using thresholds equivalent to the 97th percentile of 974 control samples in each laboratory, 1051 (97.9%) of 1074 samples were concordant. On the retested TEDDY samples, discordance decreased from 4 to 1.8% for IA-2A (n = 604 samples; P = 0.02) and from 15.4 to 2.7% for GADA (n = 515 samples; P < 0.0001). Conclusion: Harmonization of GADA and IA-2A is feasible using large volume working calibrators and common protocols and is an effective approach to ensure consistency in autoantibody measurements.


  • Open Access

    Technologies for Diabetes Genomics

    by Patricia W. Mueller

    The genetic risk for diabetes largely depends on the type of diabetes and the penetrance and severity of the effect of the contributing genes. This ranges from the high-risk mutations of neonatal diabetes and maturity-onset diabetes of the young to the lower, but still significant, risk conferred by common human leukocyte antigen alleles in type 1 diabetes to the still-lower risk conferred by the common variants associated with type 2 diabetes. There are many new molecular technologies, each with their own set of methodological issues, that have been used for genome-wide association studies and that can be used for determining the genetic risk for these various types of diabetes. These technologies include whole genome single nucleotide polymorphism microarrays, high-throughput polymorphism analyzers, next-generation sequencers, and copy-number variant technologies.


  • Open Access

    Urinary Albumin Excretion in Children: Factors Related to Elevated Excretion in the United States Population

    by Patricia W. Mueller, Samuel P. Caudill

    Past population studies have indicated a higher prevalence of high albumin excretion in children than in adults. In this study, NHANES III United States population data was analyzed to study factors associated with elevated albumin excretion in children 8 to 18 years of age. The analysis confirmed a higher prevalence of albumin values > 30 mg/g creatinine and > 200 mg/g creatinine in children than in adults, and indicated that girls are two to three times more likely to have albumin excretion above these levels than boys. Neither hypertension nor reported diabetes - major factors influencing albumin excretion in adults - accounted for the higher excretion levels in children. The higher excretion levels were not associated with prescription medications or a poor rating of the child's overall health status by a physician. The higher prevalence is influenced by puberty stage and is more likely to occur in children with lower than average body mass index, independent of the relationship with urine creatinine excretion. The increased prevalence of high albumin excretion is probablv associated with normal development in children, but an increased susceptibility to chronic diseases in the future among the children with high excretion cannot be ruled out.


  • Open Access

    Study Design and Data Analysis in Clinical and Environmental Models of Nephrotoxicity

    by Patricia W. Mueller

    Protocols for clinical studies of nephrotoxicity may include several elements. They include background information, study objectives, study design, data handling and analysis, organization and administration, and methods and definitions. Response variables used to indicate the development of clinically apparent renal disease should be clearly defined. Susceptibility factors such as diabetes, hypertension, cardiovascular disease, obesity, smoking history, and genetic factors may influence the development of renal disease and other health outcomes. These factors may also affect the pattern of abnormal biomarkers that appear during the development of renal disease. Some individuals who are normal by standard clinical criteria will be in various stages of disease development and will have abnormal biomarker levels. With all approaches, an adequate baseline assessment of biomarker values is critically important. Consistent findings among studies reinforce conclusions.

  • Open Access

    An in-depth examination of the excretion of albumin and other sensitive markers of renal damage in mild hypertension*

    by Patricia W. Mueller, W. Dallas Hall, Samuel P. Caudill, Mary Louise MacNeil, Arvin Arepally

    In an in-depth examination to better define the renal effects of mild hypertension, we used urinary proteins to indicate damage to the glomerulus (albumin), tubular reabsorption capability (retinolbinding protein), and turnover of tubular tissue (alanine aminopeptidase and N-acetyl-β-D-glucosaminidase) in a group of 18 people with mild hypertension not associated with diabetes and a control group (n = 12). The participants’ activity was controlled on a high normal salt diet for 3 days followed by a low salt diet for 4 days. Two distinct patterns of albumin excretion were evident in the hypertensive group: 22% had elevated, highly variable excretion patterns, and the rest had tightly grouped values below 16 mg/g creatinine, 16 µg/min, or 16 mg/L, with the lowest within-person biological variability given by albumin calculated as a ratio to creatinine. Albumin and NAG excretion primarily correlated with systolic blood pressure and the best correlations were given by ratios to creatinine. A marked decrease in salt excretion of 71% (to 50.8 mEq/day) resulted in significant (P < .0005) decreases in systolic (13.9 mm Hg), diastolic (6.4 mm Hg), and mean arterial pressures (8.9 mm Hg) only in the group with mild hypertension. However, albumin excretion did not decrease when dietary salt content was lowered. The group with hypertension also had higher urinary excretion of lysosomal N-acetyl-β-D-glucosaminidase (P < .01), and whites in the group had a higher excretion of retinol-binding protein than did whites in the control group (P < .02). Retinol-binding protein values, however, were within the normal range, indicating that the elevated albumin values were the result of changes in selectivity of the glomerulus. Am J Hypertens 1995;8:1072–1082